Landiolol
Rapibylk (landiolol hydrochloride) is an intravenous prescription medication used as a beta-blocker to help control rapid heart rate. It comes as a lyophilized powder in a single-dose vial, equivalent to 280 mg of landiolol base, manufactured by AOP Orphan Pharmaceuticals GmbH. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Rapibylk (landiolol hydrochloride) is an intravenous prescription medication used as a beta-blocker to help control rapid heart rate. It comes as a lyophilized powder in a single-dose vial, equivalent to 280 mg of landiolol base, manufactured by AOP Orphan Pharmaceuticals GmbH. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Landiolol",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Landiolol — ANDA 217202 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217202"
}
]
|
| identifier | ANDA217202 |
| issued | 2016-09-16 |
| keyword |
[
"drug-manufacturers",
"health-care",
"medications",
"pharmaceuticals",
"public-health"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Landiolol |
